文献速递妇科肿瘤

tRNA衍生小RNA 3'U-tRFValCAC促进卵巢癌肿瘤迁移和早期进展

tRNA-derived small RNA 3'U-tRFValCAC promotes tumour migration and early progression in ovarian cancer.
PubMed 文献 · Eur J Cancer · 2022-12-10

研究探讨tRNA衍生小RNA片段3'U-tRFValCAC在卵巢癌中的作用与临床价值,体外实验显示其促进SK-OV-3和OVCAR-3细胞生长与迁移,两个独立队列(OVCAD n=100;TU Munich n=103)分析表明其高水平与早期进展风险增高和生存更差相关,且基于该标志物的多变量模型改善风险分层。

要点

  • 3'U-tRFValCAC转染SK-OV-3和OVCAR-3细胞后呈剂量依赖性显著增加细胞生长和迁移。
  • 肿瘤3'U-tRFValCAC水平升高与一线铂类化疗后早期进展风险显著增高和生存更差相关,独立于临床病理数据、化疗反应和残留肿瘤。
  • 3'U-tRFValCAC拟合的多变量模型较疾病既定标志物改善风险分层并在预测治疗结局中提供更优临床净获益。

核心结论

  • 3'U-tRFValCAC促进肿瘤细胞生长和迁移,并支持上皮性卵巢癌的现代风险分层和预后评估。

研究设计与样本

  • 体外研究使用SK-OV-3和OVCAR-3细胞,转染后分别以CCK8和伤口愈合实验评估细胞生长和迁移。
  • 3'U-tRFs水平经3'端RNA多聚腺苷酸化后采用逆转录定量PCR(RT-qPCR)检测。
  • 采用筛查队列OVCAD(n=100)和机构独立验证队列TU Munich(n=103)进行生存分析,临床终点为疾病进展和患者死亡。
  • 采用Bootstrap分析进行内部验证,并使用决策曲线分析评估疾病预后方面的临床获益。

主要发现

  • 3'U-tRFValCAC转染SK-OV-3和OVCAR-3细胞后呈剂量依赖性显著增加细胞生长和迁移。
  • 肿瘤3'U-tRFValCAC水平升高与一线铂类化疗后早期进展风险显著增高和生存更差相关,独立于患者临床病理数据、化疗反应和残留肿瘤。
  • 3'U-tRFValCAC拟合的多变量模型较疾病既定标志物改善风险分层并在预测治疗结局中提供更优临床净获益。

关键数值与推荐

  • 筛查队列OVCAD样本量为n=100,机构独立验证队列TU Munich样本量为n=103。
  • 3'U-tRFValCAC来源于pre-tRNAValCAC。
  • 3'U-tRFs检测方法为3'端RNA多聚腺苷酸化后逆转录定量PCR(RT-qPCR)。
  • 体外功能实验使用SK-OV-3和OVCAR-3细胞系。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Despite recent advances in epithelial ovarian cancer (EOC) management, the highly heterogenous histological/molecular tumour background and patients' treatment response obstructs personalised prognosis and therapeutics. Herein, we have studied the role and clinical utility of the novel subclass of tRNA-derived small RNA fragments emerging via 3'-trailer processing of pre-tRNAs (3'U-tRFs) in EOC. METHODS: SK-OV-3 and OVCAR-3 cells were used for in vitro study. Following transfection, cell growth and migration were assessed by CCK8 and wound healing assays, respectively. 3'U-tRFs levels were assessed by reverse transcription quantitative PCR (RT-qPCR), following 3'-end RNA polyadenylation. A screening (OVCAD, n = 100) and institutionally independent validation (TU Munich, n = 103) cohorts were employed for survival analysis using disease progression and patients' death as clinical end-points. Bootstrap analysis was performed for internal validation, and decision curve analysis was used to evaluate clinical benefit on disease prognosis. RESULTS: Following primary clinical assessment, target prediction and gene ontology analyses, the 3'U-tRFValCAC (derived from pre-tRNAValCAC) was highlighted to regulate cell proliferation and adhesion, and to correlate with inferior patients' outcome. 3'U-tRFValCAC transfection of SK-OV-3 and OVCAR-3 cells resulted in significantly increased cell growth and migration, in a dose-dependent manner. Elevated tumour 3'U-tRFValCAC levels were associated with significantly higher risk for early progression and worse survival following first-line platinum-based chemotherapy, independently of patients' clinicopathological data, chemotherapy response, and residual tumour. Interestingly, 3'U-tRFValCAC-fitted multivariate models improved risk stratification and provided superior clinical net benefit in prediction of treatment outcome compared to disease established markers. CONCLUSIONS: 3'U-tRFValCAC promotes tumour cell growth and migration and supports modern risk stratification and prognosis in EOC.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Panoutsopoulou K, Magkou P, Dreyer T, et al. tRNA-derived small RNA 3'U-tRFValCAC promotes tumour migration and early progression in ovarian cancer. Eur J Cancer. 2022. PMID: 36599181. doi:10.1016/j.ejca.2022.11.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。